Cingulate grants 20,000 stock options to director

Cingulate Inc. director Thomas Jeffrey Hargroves received a grant of 20,000 stock options for Common Stock at an exercise price of $4.43 per share.

Rhea-AI Filing Summary

Cingulate Inc. director Thomas Jeffrey Hargroves received a grant of 20,000 stock options for Common Stock at an exercise price of $4.43 per share. The options vest on the earlier of the one-year anniversary of the grant date and the date of Cingulate’s 2027 annual meeting of stockholders, and expire on 2036-07-16. Following this grant, he holds 20,000 stock options directly. The grant was not reported under a Rule 10b5-1 trading plan.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Hargroves Thomas Jeffrey

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to Buy) F1	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to Buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.

Key Figures

Stock options granted: 20,000 options Exercise price: $4.43 per share Expiration date: 2036-07-16 +1 more

4 metrics

Stock options granted 20,000 options Grant of Stock Option (right to Buy) to director on 2026-07-16

Exercise price $4.43 per share Conversion or exercise price of granted stock options

Expiration date 2036-07-16 Expiration date of the granted stock options

Post-grant derivative holdings 20,000 options Total stock options held directly by Hargroves after the grant

Key Terms

Stock Option (right to Buy), exercise price, vesting, Rule 10b5-1

4 terms

Stock Option (right to Buy) financial

"security title is listed as Stock Option (right to Buy) relating to Common Stock"

exercise price financial

"The option has a conversion or exercise price of 4.4300 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests on the earlier of the one-year anniversary and the 2027 annual meeting."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Rule 10b5-1 regulatory

"The grant was not reported under a Rule 10b5-1 trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cingulate Inc. (CING) report for Thomas Jeffrey Hargroves?

Cingulate reported that director Thomas Jeffrey Hargroves received a grant of 20,000 stock options for Common Stock. The options have an exercise price of $4.43 per share, are held directly, and expire on 2036-07-16.

What is the exercise price and expiration date of the new CING stock options?

The granted stock options have an exercise price of $4.43 per share and expire on 2036-07-16. These options give the right to buy Cingulate Common Stock at that price until the stated expiration date.

How do the 20,000 Cingulate (CING) stock options granted to Hargroves vest?

The 20,000 stock options vest on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of Cingulate Inc.’s 2027 annual meeting of stockholders, creating a single vesting event tied to time or the meeting.

How many Cingulate (CING) derivative securities does Hargroves hold after this grant?

After the reported grant, Thomas Jeffrey Hargroves holds a total of 20,000 stock options directly. These options each relate to one share of Cingulate Common Stock, subject to vesting and exercisable at $4.43 per share before expiration.

Was the latest Cingulate (CING) option grant to Hargroves made under a Rule 10b5-1 plan?

No. The transaction is indicated as not made pursuant to a Rule 10b5-1 trading plan. This suggests the grant was a standard equity award rather than executed under a pre-arranged trading program for automatic transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 07:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hargroves Thomas Jeffrey

(Last) (First) (Middle)

1901 W. 47TH PLACE

(Street)

KANSAS CITY KANSAS 66205

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to Buy)	$4.43	07/16/2026		A		20,000		(1)	07/16/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.

	/s/ Shane J. Schaffer, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)